Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Brain glioblastoma is a WHO grade IV malignant astrocytic tumor that arises from the brain, usually the cerebral hemispheres. It is characterized by poorly differentiated astrocytes, cellular polymorphism, nuclear atypia, and increased mitotic activity. It is also called glioblastoma multiforme of the brain or grade IV astrocytic tumour of brain. Recognized related subtypes include giant cell glioblastoma, gliosarcoma, and brain stem glioblastoma. Prevalence is not certified in this packet.
No phenotype annotations, characteristic clinical findings, or age-of-onset information are certified in this packet, so symptoms are not described here. Presentation is expected to vary between individuals.
No genes are listed for brain glioblastoma in this packet, so its genetic basis is not characterized here. No inheritance pattern is certified.
No diagnostic methods, diagnostic criteria, or newborn screening information are certified in this packet. The definition describes the tumor histologically as showing poorly differentiated astrocytes, cellular polymorphism, nuclear atypia, and increased mitotic activity.
Treatment coverage is not certified in this packet, and no FDA-approved treatments are listed. In general descriptions of oncologic care, treatment planning depends on disease stage, tumor characteristics, and overall health, and management often involves a multidisciplinary oncology team that may use surgery, local therapies such as radiation, systemic approaches, and supportive care, with goals that may be curative or focused on symptom control. Orphan drug designations are recorded for several agents under investigation in glioblastoma multiforme, including cell-based, radiosensitizing, and small-molecule approaches; designation is not approval. One designated agent is recorded as withdrawn and is not a current development.
22 trials found
According to the definition in this packet, the prognosis of brain glioblastoma is poor. Survival figures and outcome data are not certified in this packet, and outcomes in oncology generally depend on tumor characteristics and response to treatment.
ClinicalTrials.gov lists numerous active studies under brain glioblastoma. Studies in this packet include NCT06815432 (Phase 1, recruiting; GPC-3 CAR T cells for recurrent GPC-3 positive glioblastoma), NCT05979064 (Phase NA, recruiting; omental tissue autograft in recurrent glioblastoma multiforme), NCT07179328 (Phase 1, recruiting; focused ultrasound blood-brain barrier disruption in high-grade glioma), and NCT06613841 (Early Phase 1, recruiting; multitracer PET and advanced MRI for metabolic profiling of glioblastoma).
Data assembled from 3 of 12 sources · Last updated Nov 18, 2026, 8:43 AM UTC